中关村：下属公司山东华素琥珀酸美托洛尔原料药获批上市

Core Viewpoint - The approval of "Succinic Acid Metoprolol API" by the National Medical Products Administration (NMPA) is expected to positively impact the company's operational performance by providing a stable raw material source for its research and development of sustained-release capsules [1] Group 1 - The company's subsidiary, Shandong Huasu Pharmaceutical Co., Ltd., has successfully passed the technical review by the NMPA [1] - The company has received the "Approval Notification for Chemical Raw Material Drug Listing Application" from the NMPA [1] - The approval is significant for the company's ongoing development of Succinic Acid Metoprolol sustained-release capsules [1]